Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men

Research output: Contribution to journalArticle


  • H Reynolds
  • CA Sabin
  • Susan Drake
  • David White
  • DJ Back
  • Deenan Pillay

Colleges, School and Institutes


Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.


Original languageEnglish
Pages (from-to)2051-2053
Number of pages3
Issue number15
Publication statusPublished - 1 Oct 2001